ArticleScience translational medicine2023
DNDI-6174 is a preclinical candidate for visceral leishmaniasis that targets the cytochrome bc
Open access · greenAbstract read
In one paragraph
Article in Science translational medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
7.2field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 25 citations in OpenAlex.
- Safety and pharmacokinetics of GSK3494245, a highly selective Leishmaniasis kinetoplastid proteasome inhibitor for the treatment of visceral leishmaniasis: A Phase 1, randomized, single ascending dose escalation study in healthy participants.PLoS neglected tropical diseases · 2026Trial
- Safety, tolerability and pharmacokinetics of DNDI-6148, a novel agent for leishmaniasis: A randomized, controlled, single ascending dose study in healthy participants.British journal of clinical pharmacology · 2026Trial
- Conserved and divergent mitochondrial assemblies in kinetoplastid parasites.Molecular cell · 2026Article
- Peptide-Enabled Nanoplatforms for Malaria and Leishmaniasis: From Intracellular Targeting to Translational Diagnostic Perspectives.ChemMedChem · 2026Review
- Chemical genetics reveals Leishmania KKT2 and CRK9 kinase activity is required for cell cycle progression.PLoS pathogens · 2026Article
- NMR spectroscopic evidence that the antileishmanial drug sodium stibogluconate comprises one predominant molecular species.Journal of inorganic biochemistry · 2026Article
- Kinetoplast-Directed Therapies: A Selective Mitochondrial Approach to Combat Leishmaniasis.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Nucleoside Analogue with Thymidine Nucleobase InhibitsACS omega · 2026Article
- Interventions for Neglected Diseases Caused by Kinetoplastid Parasites: A One Health Approach to Drug Discovery, Development, and Deployment.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Identification of Substituted 4-Aminocinnolines as Broad-Spectrum Antiparasitic Agents.ACS infectious diseases · 2025Article
- Nucleoside Analogues for Chagas Disease and Leishmaniasis Therapy: Current Status and Future Perspectives.Molecules (Basel, Switzerland) · 2024Review
- Identification and Validation of Compounds TargetingACS infectious diseases · 2024Article
- Discovery and Optimization of Tambjamines as a Novel Class of Antileishmanial Agents.Journal of medicinal chemistry · 2024Article
- Short-course combination treatment for experimental chronic Chagas disease.Science translational medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
38 authors at 12 institutions in 7 countries.
Stéphanie BraillardDrugs for Neglected Diseases initiative (DNDi), Chemin Camille-Vidart 15, 1202 Geneva, Switzerland.ORCID 0000-0002-6354-3059
Martine KeenanEpichem Pty Ltd., Perth, Western Australia, Australia.ORCID 0009-0003-1218-0520
Karen J BreeseEpichem Pty Ltd., Perth, Western Australia, Australia.ORCID 0000-0001-8368-9066
Jacob HeppellEpichem Pty Ltd., Perth, Western Australia, Australia.
Michael AbbottEpichem Pty Ltd., Perth, Western Australia, Australia.ORCID 0009-0008-8087-0802
Rafiqul IslamEpichem Pty Ltd., Perth, Western Australia, Australia.
David M ShacklefordCentre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville 3052, Australia.ORCID 0000-0002-8229-6591
Kasiram KatneniCentre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville 3052, Australia.
Elly CrightonCentre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville 3052, Australia.
Gong ChenCentre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville 3052, Australia.
Rahul PatilCentre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville 3052, Australia.
Given LeeCentre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville 3052, Australia.
Karen L WhiteCentre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville 3052, Australia.ORCID 0000-0002-3116-6949
Sandra CarvalhoWellcome Centre for Anti-infectives Research, School of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, UK.ORCID 0000-0001-6695-1683
Richard J WallWellcome Centre for Anti-infectives Research, School of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, UK.
Giulia ChemiDrug Discovery Unit, Wellcome Centre for Anti-infectives Research, School of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, UK.
Fabio ZuccottoDrug Discovery Unit, Wellcome Centre for Anti-infectives Research, School of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, UK.ORCID 0000-0002-3888-7423
Silvia GonzálezGlobal Health Medicines R&D, GlaxoSmithKline, Tres Cantos, Madrid 28760, Spain.ORCID 0009-0005-6551-0209
Maria MarcoGlobal Health Medicines R&D, GlaxoSmithKline, Tres Cantos, Madrid 28760, Spain.ORCID 0000-0002-2442-0021
Julianna DeakyneGlobal Investigative Safety, GSK, Collegeville, PA, USA.ORCID 0000-0001-5228-5472
David StandingMedicine Design, GSK, Stevenage, UK.ORCID 0009-0009-3404-3117
Gino BrunoriGlobal Investigative Safety, GSK, Ware, UK.
Jonathan J LyonGlobal Investigative Safety, GSK, Ware, UK.ORCID 0009-0002-6038-7799
Pablo Castañeda-CasadoDiscovery DMPK, GSK, Tres Cantos, Madrid, Spain.ORCID 0000-0002-0514-7306
Isabel CaminoDiscovery DMPK, GSK, Tres Cantos, Madrid, Spain.ORCID 0009-0005-4024-6894
Maria S Martinez MartinezDiscovery DMPK, GSK, Tres Cantos, Madrid, Spain.ORCID 0000-0001-7894-2135
Bilal ZulfiqarDiscovery Biology, Griffith University, Nathan, Queensland 4111, Australia.ORCID 0000-0001-5720-4301
Vicky M AveryDiscovery Biology, Griffith University, Nathan, Queensland 4111, Australia.ORCID 0000-0003-4914-2299
Pim-Bart FeijensLaboratory of Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.ORCID 0000-0001-9510-3501
Natascha Van PeltLaboratory of Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.ORCID 0000-0001-8922-7903
An MatheeussenLaboratory of Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.ORCID 0000-0002-7507-1634
Sarah HendrickxLaboratory of Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.ORCID 0000-0002-1571-7296
Louis MaesLaboratory of Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.ORCID 0000-0002-2324-9509
Guy CaljonLaboratory of Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.ORCID 0000-0002-4870-3202
Vanessa YardleyFaculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK.
Susan WyllieWellcome Centre for Anti-infectives Research, School of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, UK.ORCID 0000-0001-8810-5605
Susan A CharmanCentre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville 3052, Australia.ORCID 0000-0003-1753-8213
Eric ChatelainDrugs for Neglected Diseases initiative (DNDi), Chemin Camille-Vidart 15, 1202 Geneva, Switzerland.ORCID 0000-0002-3158-7743
Monash University · AUUniversity of Antwerp · BEDepartment of the Premier and Cabinet · AUUniversity of Dundee · GBGlaxoSmithKline (Spain) · ESDrugs for Neglected Diseases Initiative · CHGlaxoSmithKline (France) · FRGriffith University · AUHealth and Safety Executive · GBAge UK · GBGlaxoSmithKline (United States) · USUniversity of London · GB
Funding
Wellcome Trust 105021Wellcome Trust 203134Wellcome Trust 218448
Abstract
New drugs for visceral leishmaniasis that are safe, low cost, and adapted to the field are urgently required. Despite concerted efforts over the last several years, the number of new chemical entities that are suitable for clinical development for the treatment of
Indexed as
LeishmaniasisLeishmaniasis, VisceralAnimalsDisease Models, AnimalRats
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.